Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MT1013
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Shaanxi Micot Technology Limited Company
Deal Size : Inapplicable
Deal Type : Inapplicable
MT1013 Clinical TRIAL In Healthy Subject
Details : MT1013 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : MT1013
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Shaanxi Micot Technology Limited Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMT-002
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : ImmunoMolecular Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
Details : IMT-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : IMT-002
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : ImmunoMolecular Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Stanford University | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 27, 2019
Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Stanford University | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norwalk GI.1 Virus
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Vaxart
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Norwalk GI.1 Virus is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Caliciviridae Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2018
Lead Product(s) : Norwalk GI.1 Virus
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Vaxart
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Undisclosed
Study Phase : Phase II
Recipient : Dance Biopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Insulin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 11, 2017
Lead Product(s) : Insulin Lispro
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Recipient : Dance Biopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
Details : SB204 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2016
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PUL-042
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Pulmotect
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PUL-042 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 02, 2015
Lead Product(s) : PUL-042
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Pulmotect
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)
Details : NGP 555 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 02, 2015
Lead Product(s) : MOD-4023
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MOD-4023 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dwarfism, Pituitary.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 16, 2015
Lead Product(s) : MOD-4023
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
